Insider Buying: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Director Buys $52,256.65 in Stock

Mersana Therapeutics, Inc. (NASDAQ:MRSNGet Rating) Director Andrew A. F. Hack bought 15,599 shares of the business’s stock in a transaction that occurred on Monday, May 23rd. The shares were acquired at an average cost of $3.35 per share, for a total transaction of $52,256.65. Following the completion of the purchase, the director now owns 8,302,999 shares in the company, valued at $27,815,046.65. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ:MRSN opened at $3.21 on Thursday. Mersana Therapeutics, Inc. has a 52 week low of $2.68 and a 52 week high of $15.34. The company’s 50 day moving average is $3.85 and its two-hundred day moving average is $5.08. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 0.18. The company has a market cap of $311.34 million, a PE ratio of -1.29 and a beta of 2.37.

Mersana Therapeutics (NASDAQ:MRSNGet Rating) last announced its quarterly earnings data on Monday, May 9th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.28). Mersana Therapeutics had a negative net margin of 8,826.73% and a negative return on equity of 119.10%. During the same quarter in the previous year, the company earned ($0.50) earnings per share. As a group, equities research analysts expect that Mersana Therapeutics, Inc. will post -2.13 EPS for the current year.

Several brokerages recently weighed in on MRSN. Robert W. Baird cut their target price on shares of Mersana Therapeutics from $23.00 to $18.00 in a research note on Tuesday, May 10th. SVB Leerink cut their target price on shares of Mersana Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, February 18th. HC Wainwright cut their target price on shares of Mersana Therapeutics from $24.00 to $19.00 in a research note on Monday, May 9th. Finally, Zacks Investment Research downgraded shares of Mersana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $17.80.

Institutional investors have recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in shares of Mersana Therapeutics by 47.2% in the 3rd quarter. Royal Bank of Canada now owns 6,941 shares of the company’s stock valued at $66,000 after buying an additional 2,226 shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in shares of Mersana Therapeutics in the 4th quarter valued at $56,000. Point72 Hong Kong Ltd acquired a new position in shares of Mersana Therapeutics in the 4th quarter valued at $57,000. Quantbot Technologies LP acquired a new stake in Mersana Therapeutics during the 1st quarter worth $37,000. Finally, Victory Capital Management Inc. acquired a new stake in Mersana Therapeutics during the 1st quarter worth $36,000. Institutional investors and hedge funds own 92.74% of the company’s stock.

Mersana Therapeutics Company Profile (Get Rating)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.

See Also

Insider Buying and Selling by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.